Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 50.0%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,200,000 shares, an increase of 50.0% from the March 31st total of 799,900 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is presently 1.1 days. Currently, 8.9% of the company’s stock are short sold.

Institutional Investors Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Sage Rhino Capital LLC boosted its position in Vincerx Pharma, Inc. (NASDAQ:VINC) by 1.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,703,413 shares of the company’s stock after purchasing an additional 16,476 shares during the period. Sage Rhino Capital LLC owned about 7.97% of Vincerx Pharma worth $1,720,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Price Performance

Vincerx Pharma stock opened at $0.73 on Friday. Vincerx Pharma has a one year low of $0.61 and a one year high of $9.37. The stock has a market capitalization of $15.63 million, a PE ratio of -0.39 and a beta of 1.10. The business’s fifty day moving average is $4.07 and its 200 day moving average is $2.07.

Vincerx Pharma (NASDAQ:VINC) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.23) EPS for the quarter. As a group, sell-side analysts expect that Vincerx Pharma will post -0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Vincerx Pharma in a research note on Tuesday, April 9th.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.